Navigation Links
NUCRYST Receives Deficiency Notice from NASDAQ
Date:8/15/2008

WAKEFIELD, MA, Aug. 15 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on August 14, 2008, it received notice from The Nasdaq Stock Market stating that, for the last 30 consecutive trading days, the Company's common shares had not maintained the minimum market value of publicly held shares ("MVPHS") of $5 million required for continued listing on The Nasdaq Global Market under Marketplace Rule 4450(a)(2) (the "Rule"). Receipt of this notice has no immediate effect on the listing of the Company's common shares. The Company has 90 calendar days, or until November 12, 2008, to regain compliance with the Rule.

The notice states that if at any time before November 12, 2008, the MVPHS of NUCRYST's common shares is $5 million or more for a minimum of 10 consecutive trading days, Nasdaq will provide written notification that the Company complies with the Rule. If the Company cannot demonstrate compliance with that Rule by November 12, 2008, Nasdaq staff will notify the Company that its securities will be delisted from The Nasdaq Global Market. If the Company receives a delisting notice, the Nasdaq Marketplace Rules would permit the Company to appeal the Nasdaq staff's determination to delist its securities to a Nasdaq Listing Qualifications Panel.

NUCRYST is currently evaluating its alternatives to resolve the listing deficiency. If the Company is unable to resolve the listing deficiency, it may apply to transfer its common shares to The Nasdaq Capital Market. In order to transfer, the Company must satisfy the continued inclusion requirements for that market which the Company believes it currently does. If the Company submits a transfer application by November 12, 2008, the initiation of the delisting proceedings will be stayed pending the Nasdaq staff's review of the application.

About NUCRYST Pharmaceuticals

NUCRYST Pharmaceutic
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NUCRYST and Smith & Nephew Revise Agreements
2. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. NUCRYST Pharmaceuticals announces 2007 third quarter results
4. NUCRYST Pharmaceuticals announces year-end results
5. NUCRYST Announces Senior Management Change
6. NUCRYST Announces Management Realignment and R&D Portfolio Change
7. NUCRYST Announces First Quarter 2008 Financial Results
8. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
9. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
10. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
11. DaVita Receives Civil Complaint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... The U.S. Pharmacopeial Convention is pleased to announce that ... at North Carolina State’s College of Veterinary Medicine has ... for Distinguished Volunteer Service—the organization’s highest award. , ... volunteer experts to direct its work to improve the ...
(Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2
... prevent the rejection of newly transplanted organs and ... entire immune systems. Such potentially life-saving treatments can, ... infections. , Now researchers at the University ... Medicine and the UNC Lineberger Comprehensive Cancer Center ...
... RICHMOND, Va., Feb. 11 Access to high quality ... healthy newborns. In the Philippines, six new birthing centers ... for women in Pili, Camarines Sur. "We want to ... care facilities, which is the most important factor in ...
... Abbott ( NYSE: ABT ),today announced it received ... (FDA) for its new, compact hematology instrument, CELL-DYN,Emerald(TM). ... hematology,platform by offering a high performance, affordable solution ... As small to mid-sized hospital ...
... is to have compassion for others , , WEDNESDAY, Feb. 11 ... person,s ability to empathize with others, suggests a U.S. study ... a sound played in a specific cage as negative by ... that cage. But a genetically different strain of mice that ...
... Feb. 11 Solos Endoscopy, Inc. (Pink Sheets: SNDY) ... its financials through the first nine months of 2008 ... Revenues generated through the nine-months of 2008 amounted to ... 2007. The Company substantially lowered its General and Administrative ...
... U.S. Surgeon General Kenneth P. Moritsugu urged members of ... nutrition knowledge and patient-care skills to prevent diseases such ... that exist in the United States and to educate ... well-being.Moritsugu, who was Deputy Surgeon General from 1998 to ...
Cached Medicine News:Health News:UNC study hints at new approaches to prevent transplant rejection 2Health News:UNC study hints at new approaches to prevent transplant rejection 3Health News:Philippine Birthing Centers Help New Mothers, Healthy Infants 2Health News:Philippine Birthing Centers Help New Mothers, Healthy Infants 3Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 2Health News:Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument 3Health News:Empathy Might Be in the Genes 2Health News:Solos Endoscopy, Inc. Posts First Nine Months Financials for 2008 on Pinksheets.com 2Health News:Registered Dietitians Can Do Much to Help Educate Americans and Eliminate Health Disparities in U.S., Says Former Surgeon General 2Health News:Registered Dietitians Can Do Much to Help Educate Americans and Eliminate Health Disparities in U.S., Says Former Surgeon General 3
(Date:1/23/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW Bio"), a ... and inoperable solid tumor cancers, announced today that CEO ... Annual Phacilitate Immunotherapy Forum in Washington D.C. ... place on January 26 at 10:30 a.m. EST at the ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... 7 Ardea,Biosciences, Inc. (Nasdaq: RDEA ) ... activity of the Company,s non-nucleoside reverse,transcriptase inhibitor (NNRTI) ... known causative agent of AIDS,including NNRTI-resistant strains., ... Conference on Retroviruses,and Opportunistic Infections (CROI) in Boston., ...
... gastrointestinal and lipid effects between ... N.J., Feb. 6 Bristol-Myers Squibb,Company (NYSE: ... study, in which,300 mg of once-daily REYATAZ(R) (atazanavir ... similar antiviral efficacy to twice-daily,lopinavir 400 mg and ...
Cached Medicine Technology:Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 2Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 2CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 4CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 5CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 6
Inquire...
...
Liquichek Elevated CRP Control is a liquid assayed serum control with elevated levels of C-Reactive Protein....
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: